Compare · DXCM vs IRMD
DXCM vs IRMD
Side-by-side comparison of DexCom Inc. (DXCM) and iRadimed Corporation (IRMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and IRMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 23.6x IRMD ($1.19B).
- Over the past year, DXCM is down 10.6% and IRMD is up 55.6% - IRMD leads by 66.2 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 5 for IRMD).
- DXCM has more recent analyst coverage (25 ratings vs 1 for IRMD).
- Company
- DexCom Inc.
- iRadimed Corporation
- Price
- $76.59+5.15%
- $94.37+0.32%
- Market cap
- $28.11B
- $1.19B
- 1M return
- +25.71%
- +8.62%
- 1Y return
- -10.56%
- +55.61%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2014
- News (4w)
- 26
- 5
- Recent ratings
- 25
- 1
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
iRadimed Corporation
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest IRMD
- Director Scharen-Guivel Hilda Frederique sold $285,000 worth of shares (3,000 units at $95.00), decreasing direct ownership by 35% to 5,598 units (SEC Form 4)
- CEO, President, Chairman Susi Roger E. sold $226,507 worth of shares (2,500 units at $90.60) as part of a pre-agreed trading plan (SEC Form 4)
- CEO, President, Chairman Susi Roger E. sold $691,044 worth of shares (7,500 units at $92.14) as part of a pre-agreed trading plan (SEC Form 4)
- CEO, President, Chairman Susi Roger E. sold $657,265 worth of shares (7,500 units at $87.64) as part of a pre-agreed trading plan (SEC Form 4)
- IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by iRadimed Corporation
- CEO, President, Chairman Susi Roger E. sold $631,341 worth of shares (7,500 units at $84.18) as part of a pre-agreed trading plan (SEC Form 4)
- CEO, President, Chairman Susi Roger E. sold $642,862 worth of shares (7,500 units at $85.71) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by iRadimed Corporation
- iRadimed Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits